Among cognitively healthy older adults, the rate of change in cerebrospinal fluid biomarkers helps predict who will develop Alzheimer’s disease.
An astrocyte protein stymies toxic interplay between Aβ oligomers and prion proteins.
Two studies strengthen the link between shut-eye and Alzheimer’s disease, and a mouse analysis of how the brain drains waste offers insight into the connection.
Screens of yeast and human-derived neurons uncover reasons for α-synuclein toxicity and potential ways to prevent it.
Deep brain stimulation restores walking and swimming abilities in rats with spinal injuries, so long as a few nerve fibers remain intact.
A meta-analysis of four large genome-wide association studies turned up 11 new risk genes for Alzheimer’s disease.
More evidence that an antisense RNA strategy might work for certain types of ALS and FTD.
A repeat expansion that causes neurodegenerative disease is transcribed both forward and backward, producing sense and antisense RNAs and multiple polypeptides.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
Some neurons stand out in the crowd. Researchers report that genomic variation among neurons in the brain is more common than originally thought.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
Changing ApoE levels in midlife influences Aβ pathology in mice, supporting an ApoE-oriented therapeutic strategy in Alzheimer’s disease.
No filters selected